Optimized management of enfortumab vedotin‐related dermatological toxicity
- 8 June 2026
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (11)
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Enfortumab vedotin‐induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic featureJournal of Cutaneous Pathology, 2024
- Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic FindingsThe American Journal of Dermatopathology, 2024
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerNew England Journal of Medicine, 2024
- Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithmJournal of the European Academy of Dermatology and Venereology, 2023
- Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”The Oncologist, 2022
- Life-threatening skin reaction with Enfortumab Vedotin: Six casesEuropean Journal of Cancer, 2022
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab VedotinThe Oncologist, 2022
- Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaNew England Journal of Medicine, 2021